Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis to acquire US cancer drug developer Endocyte for $2.1bn

pharmaceutical-technologyOctober 22, 2018

Tag: Novartis , acquisition , endocyte , cancer drug

PharmaSources Customer Service